Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(humanitarian device exemption)
938 results
  • Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion. [Case Reports]
    Respir Med Case Rep 2019; 28:100927Tello K, Hoffmann A, … Koczulla AR
  • We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a s…
  • Advances in primary mitochondrial myopathies. [Journal Article]
    Curr Opin Neurol 2019; 32(5):715-721de Barcelos IP, Emmanuele V, Hirano M
  • CONCLUSIONS: The prospects of effective therapies that improve the quality of life for patients with mitochondrial myopathy underscore the necessity for definitive diagnoses natural history studies for better understanding of the diseases.
  • The history of Transcatheter Aortic Valve Implantation (TAVI)-A personal view over 25 years of development. [Review]
    Cardiovasc Revasc Med 2019Figulla HR, Franz M, Lauten A
  • In the early 1990s, the idea of Transcatheter Aortic Valve Implantation (TAVI) emerged from clinicians by the insight that the long-term hemodynamic and clinical results of aortic balloon valvuloplasty to treat aortic stenonosis were not satisfying. Thus, Anderson and Cribier developed the balloon-expandable and Figulla and Laborde the self-expendable TAVI systems. Sceptical views by the surgical…
  • Unproven stem cell therapies: is it my right to try? [Journal Article]
    Ann Ist Super Sanita 2019 Apr-Jun; 55(2):179-185Riva L, Campanozzi L, … Tambone V
  • CONCLUSIONS: We stress the need, in the age of cellular therapies, for a commitment to support vulnerable patients and to strengthen awareness among the public about the substantial boundary that differentiates experimental therapies from unproven therapies. There should not be a "right to try" something that is unsafe but rather approved treatments and in line with good clinical practice. The trend, which emerged on this issue from our study, is quite different, confirming the urgent need to improve health information so that it is as complete as possible.
  • Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report. [Journal Article]
    Clin Drug Investig 2019; 39(10):1003-1007Pan J
  • Dabrafenib plus trametinib is US Food and Drug Administration approved combination therapy for use in patients with BRAF V600E-mutant non-small cell lung cancer, but information on use outside of clinical trials is limited. We report the case of a 70-year-old Asian woman (never smoker) who was diagnosed with lung adenocarcinoma in May 2014. Testing at diagnosis was negative for programmed death l…
New Search Next